KDMA1 (LSD1) has oncogenic functions in prostate cancers by AR co-activation, suppression of p53, and activation of c-Myc expression, and the development of KDM inhibitors as anticancer agents (e.g., cyclopropylamines) paves the way to promising epigenetic treatment options. Here, MYC is linked to prostate carcinoma.